Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Optimizing long-term anticoagulation by patient self-management?]

A Bernardo1

  • 1Herz-Kreislauf-Klinik, Bad Berleburg.

Zeitschrift Fur Kardiologie
|December 19, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Modification of polyester filters with synthesized copper nanoparticles for use as biocide in a real environment.

Applied nanoscience·2022
Same author

Primary melanoma of the bladder: a case report and review of the literature.

European review for medical and pharmacological sciences·2021
Same author

Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].

ESMO open·2021
Same author

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).

ESMO open·2021

Patient self-management of oral anticoagulation improves treatment quality and reduces complication risks. Studies show patients achieve superior anticoagulation control through easy-to-learn self-management techniques.

Area of Science:

  • Cardiology
  • Pharmacology
  • Patient Management

Context:

  • Long-term anticoagulation therapy requires careful monitoring to prevent complications.
  • Optimizing anticoagulation control is crucial for patient prognosis and quality of life.
  • Patient engagement in therapy management can enhance treatment outcomes.

Purpose:

  • To evaluate the efficacy and safety of patient self-management in oral anticoagulation.
  • To assess the level of anticoagulation control achieved by patients managing their own therapy.
  • To determine the impact of self-management on hemorrhagic and thromboembolic complication rates.

Summary:

  • Over 10 years, 1244 patients were trained in self-managing oral anticoagulation.
  • Follow-up on 387 patients showed 81.5% of self-determined prothrombin time (PT) measurements were within the target range.

Related Experiment Videos

  • The incidence of major bleeding was 0.33% per year, and thromboembolic complications were 0.25% per year.

    • Impact:

    • Patient self-management leads to superior anticoagulation control.
    • It is associated with a reduced risk of major bleeding and thromboembolic events.
    • Empowering patients in their anticoagulation therapy improves prognosis and quality of life.